Glucose control during 3-month treatment with bihormonal artificial pancreas versus current diabetes care in patients after total pancreatectomy: study protocol for the PANORAMA randomized crossover trial

Patients undergoing total pancreatectomy (TP) will develop insulin-dependent diabetes, which is challenging to manage due to the complete absence of insulin and glucagon1. In recent years, the first European Commission-marked bihormonal artificial pancreas (BIHAP; Inreda Diabetic, Goor, the Netherla...

Full description

Saved in:
Bibliographic Details
Main Authors: Lesemann, Charlotte A. (Author) , Veldhuisen, Charlotte L. van (Author) , Rompen, Ingmar F. (Author) , Bouwense, Stefan A. (Author) , Bosscha, Koop (Author) , Busch, Olivier R. (Author) , Dijkgraaf, Marcel G. W. (Author) , Eijck, Casper H. J. van (Author) , Haan, Job S. de (Author) , Haen, Roel (Author) , Hingh, Ignace H. J. de (Author) , Meijer, V. de (Author) , Nijkamp, Maarten W. (Author) , Mieog, J. Sven D. (Author) , Molenaar, I. Quintus (Author) , Santvoort, Hjalmar. (Author) , Stommel, Martijn W. J. (Author) , Voermans, Rogier P. (Author) , Wilmink, Johanna W. (Author) , De Vries, J. Hans (Author) , Besselink, Marc G. (Author)
Format: Article (Journal) Editorial
Language:English
Published: February 2026
In: BJS open
Year: 2026, Volume: 10, Pages: 1-2
ISSN:2474-9842
DOI:10.1093/bjsopen/zraf151
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/bjsopen/zraf151
Get full text
Author Notes:Charlotte A Leseman, Charlotte L van Veldhuisen, Ingmar F Rompen, Stefan A Bouwense, Koop Bosscha, Olivier R Busch, Marcel GW Dijkgraaf, Casper HJ van Eijck, Job S de Haan, Roel Haen, Ignace HJ de Hingh, V de Meijer, Maarten W Nijkamp, J Sven D Mieog, I Quintus Molenaar, Hjalmar C van Santvoort, Martijn WJ Stommel, Rogier P Voermans, Johanna W Wilmink, J Hans De Vries and Marc G Besselink, on behalf of the Dutch Pancreatic Cancer Group
Description
Summary:Patients undergoing total pancreatectomy (TP) will develop insulin-dependent diabetes, which is challenging to manage due to the complete absence of insulin and glucagon1. In recent years, the first European Commission-marked bihormonal artificial pancreas (BIHAP; Inreda Diabetic, Goor, the Netherlands) was introduced as a novel approach for the treatment of type 1 diabetes, with encouraging results2. Recently, the BIHAP was tested for the first time in patients after TP3. In a pilot study3, diabetes treatment with the BIHAP versus current diabetes treatment was compared in 10 patients after TP over a period of 7 days. This randomized crossover clinical trial demonstrated that the BIHAP can provide superior glucose control compared with current diabetes care (median time spent in range 78% (interquartile range (i.q.r.) 71-83%) versus 57% (i.q.r. 52-81%), respectively; P = 0.03).
Item Description:Online veröffentlicht: 20. Januar 2026
Gesehen am 25.03.2026
Physical Description:Online Resource
ISSN:2474-9842
DOI:10.1093/bjsopen/zraf151